Premium
Successful treatment of acquired pure red cell aplasia (PRCA) by allogeneic peripheral blood stem cell transplantation
Author(s) -
Tseng ShihBin,
Lin ShengFung,
Chang ChaoSung,
Liu TaChih,
Hsiao HuiHua,
Liu YiChang,
Tsai HuiJen,
Chen TyenPo
Publication year - 2003
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.10421
Subject(s) - pure red cell aplasia , medicine , aplasia , transplantation , cyclophosphamide , stem cell , platelet , gastroenterology , aplastic anemia , refractory (planetary science) , granulocyte colony stimulating factor , immunology , surgery , chemotherapy , anemia , bone marrow , biology , genetics , astrobiology
A 37‐year‐old male was treated successfully by peripheral blood stem cell transplantation (PBSCT) from his HLA‐identical sister for refractory acquired pure red cell aplasia (PRCA). The conditioning regimen was cyclophosphamide 50 mg/kg/day for 4 days plus TBI 300 cGy in a single fraction. Absolute neutrophil count (ANC) >500/μl and platelet counts >20,000/μl were achieved 8 days after PBSCT without transfusion. Chimerism study on day 218 revealed full donor chimerism. The hemoglobin level was stable around 12–13 g/dl with normal leukocyte and platelet counts after PBSCT during a long follow‐up period. From this case, PBSCT should be considered for patients with refractory acquired PRCA with an HLA‐identical donor. Am. J. Hematol. 74:273–275, 2003. © 2003 Wiley‐Liss, Inc.